Home

CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $361 million in 92 projects around the world.

361

$million

Invested

92

innovative

Projects

12

different

Countries

19

focused on new classes

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More


2020-2021

Annual Report

CARB-X closed its fifth fiscal year on July 31, 2021 with US$361 million awarded to 92 projects funding since inception

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Infectious Diseases Interventions, Wellcome Trust. Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

GHTC logo and Innovation award noticeProud recipient of the

2020 Innovating for Impact Partnership Award

from the Global Health Technologies Coalition (GHTC) 

Watch video

 

 

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners

Events

Events

10.22.21

CA 

ID Week 2021

10.22.21

Webinar 

CARB-X WEBINAR: European Celebration of 5 Years of Progress with CARB-X

10.24.21

 

World Health Summit

CARB-X News

  • 10.12.2021  |  CARB-X 2020-21 Annual Report: CARB-X surpasses all goals in first five years in combatting antibiotic resistant-bacteria full release

  • 07.29.2021  |  CARB-X celebrates five years of progress in early-stage product development against antibiotic-resistant bacteria full release

  • 06.08.2021  |  CARB-X is funding Accelerate Diagnostics to develop a rapid optical imaging diagnostic for sepsis and serious antibiotic-resistant bacterial infections full release

See All News

In The News

  • 10.13.2021  |  Antibiotic Resistance: How CARB-X Helps New Companies Get a Running Start full story

  • 09.26.2021  |  Governments fall behind in race to stem antimicrobial resistance full story

  • 08.13.2021  |  At 5 years, CARB-X celebrates progress on antibiotic development full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.